We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-1.1%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$3.36B
AUM Growth
-$17.8M
Cap. Flow
+$178M
Cap. Flow %
5.3%
Top 10 Hldgs %
63.12%
Holding
56
New
4
Increased
15
Reduced
6
Closed
8

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$120M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.1M
3
FATE icon
Fate Therapeutics
FATE
+$33.5M
4
ADPT icon
Adaptive Biotechnologies
ADPT
+$23.6M
5
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$22.8M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$39.6M
2
BNR
Burning Rock Biotech
BNR
+$32.7M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$25.5M
4
RLAY icon
Relay Therapeutics
RLAY
+$18.8M
5
ADVM
Adverum Biotechnologies
ADVM
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 86.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
51
DELISTED
bluebird bio
BLUE
– –
-70,638
Closed -$39.6M
CCCC icon
52
C4 Therapeutics
CCCC
$387M
– –
-40,000
Closed -$1.32M
IOVA icon
53
Iovance Biotherapeutics
IOVA
$1.93B
– –
-550,000
Closed -$25.5M
AMRS
54
CALL
DELISTED
Amyris Inc.
AMRS
– –
-2,000,000
Closed -$12.3M
GBT
55
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-50,000
Closed -$2.17M
BMY.RT
56
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
– –
-6,250,000
Closed -$4.31M
1 2
3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Casdin Capital held 56 positions worth $3.36B, down 0.53% from $3.38B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Casdin Capital deployed $178M of net new capital in Q1 2021, opening 4 new positions and adding to 15 existing holdings. Its largest new stake was Orchard Therapeutics plc American Depositary Shares: 321,543 shares worth $23.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 84% a quarter earlier.

On the sell side, the largest reduction was Burning Rock Biotech, an estimated $32.7M trimmed.

  • Casdin Capital's largest Q1 2021 buy was Orchard Therapeutics plc American Depositary Shares: 321,543 shares worth $23.3M.
  • Casdin Capital added most to Exact Sciences in Q1 2021, an estimated $120M increase.
  • Casdin Capital's biggest Q1 2021 reduction was Burning Rock Biotech, cutting an estimated $32.7M.
  • Casdin Capital fully exited bluebird bio in Q1 2021, selling an estimated $39.6M.
  • Casdin Capital's ten largest holdings make up 63% of its $3.36B portfolio in Q1 2021.
  • Casdin Capital opened 4 new positions and closed 8 in Q1 2021.
  • Casdin Capital's portfolio value fell 0.53% quarter-over-quarter to $3.36B.

Based on Casdin Capital's 13F filing for Q1 2021, filed 17 May 2021.